Contact number:
400 007 5658
R&D
With the R&D and manufacture of controlled-release drug products as the core business, Anbison focuses on development of high-end controlled-release dosage forms and finished dosage forms that are inherently difficult to manufacture. Meanwhile, we are actively expanding to 505b(2) drugs and complex long-acting injectables.
To learn more, please slide the window left and right
Product Name | Status | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|
Topiramate Extended-release Capsules | Submitted to NMPA | ||||
Levetiracetam extended-release Granule | Submitted to NMPA | ||||
Mesalamine Extended Release Capsules | Submitted to NMPA/FDA | ||||
Mesalazine gastro-resistant prolonged-release granules | Submitted to NMPA | ||||
Mesalazine Enteric-coated Tablets(Gsatro Resistant Prolonged Release) | Submitted to NMPA | ||||
Compound Sodium Valproate and Valproic Acid Sustained Release Tablets | Submitted to NMPA | ||||
Agomelatine Tablets | Submitted to NMPA | ||||
Exemestane Tablets | Submitted to NMPA | ||||
Flurbiprofen Cataplasms | Submitted to NMPA | ||||
Amlodipine and Benazepril Hydrochloride Capsules | Submitted to NMPA | ||||
Cytarabine for Injection | Submitted to NMPA | ||||
Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets | Submitted to NMPA | ||||
Benidipine Hydrochloride Tablets | Submitted to NMPA | ||||
Mesalazine Suppositories | Submitted to NMPA | ||||
Pranoprofen Eye Drops | Submitted to NMPA | ||||
Tafluprost Eye Drops | Submitted to NMPA | ||||
Cyclosporin Eye Drops/cyclosporine ophthalmic emulsion | Submitted to FDA |